|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.36 CNY | -1.04% |
|
+4.39% | +26.25% |
| 12/07 | Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection | MT |
| 09/07 | Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9% | MT |
Shanghai Shyndec Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 13,945.24 million compared to CNY 12,556.28 million a year ago. Net income was CNY 567.52 million compared to CNY 648.79 million a year ago.
Basic earnings per share from continuing operations was CNY 0.5526 compared to CNY 0.6318 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +26.25% | 2.31B | |
| +33.76% | 10.31B | |
| +40.41% | 5.23B | |
| -15.24% | 4.62B | |
| +11.62% | 3.52B | |
| -38.78% | 1.78B | |
| -44.54% | 1.69B | |
| -0.50% | 1.64B | |
| +0.03% | 1.59B | |
| -29.87% | 1.36B |
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. 
